TY - JOUR
T1 - Targeted Treatment of Chronic Lymphocytic Leukemia
T2 - Clinical Utility of Acalabrutinib
AU - Vitale, Candida
AU - Gibbons, Jamie Lynn
AU - Ferrajoli, Alessandra
N1 - Publisher Copyright:
© 2021 Vitale et al. This work is published and licensed by Dove Medical Press Limited.
PY - 2021
Y1 - 2021
N2 - In chronic lymphocytic leukemia (CLL), a deeper understanding of the disease biology led over the last decade to the development and clinical use of different targeted drugs, including Bruton tyrosine kinase (BTK) inhibitors. The first BTK inhibitor approved for clinical use is ibrutinib, which showed excellent efficacy and good tolerability. More recently, the interest is growing for novel more selective BTK inhibitors that may reduce the off-target effects of the drug, thus minimizing side effects and subsequent treatment interruptions or discontinuations. Acalabrutinib is an orally administered irreversible BTK inhibitor, characterized by the lack of inhibition towards other kinases. In this review, we present the most recent data from clinical trials on the clinical efficacy of acalabrutinib and acalabrutinib-based combinations for the treatment of patients with relapsed/refractory and treatment-naïve CLL. We delineate the safety profile of the drug, describe side effects of interest and discuss the clinical management of patients receiving acalabrutinib. Due to its efficacy and the favorable safety profile, acalabrutinib has emerged as a viable therapy option in the current landscape of multiple approved treatments for CLL.
AB - In chronic lymphocytic leukemia (CLL), a deeper understanding of the disease biology led over the last decade to the development and clinical use of different targeted drugs, including Bruton tyrosine kinase (BTK) inhibitors. The first BTK inhibitor approved for clinical use is ibrutinib, which showed excellent efficacy and good tolerability. More recently, the interest is growing for novel more selective BTK inhibitors that may reduce the off-target effects of the drug, thus minimizing side effects and subsequent treatment interruptions or discontinuations. Acalabrutinib is an orally administered irreversible BTK inhibitor, characterized by the lack of inhibition towards other kinases. In this review, we present the most recent data from clinical trials on the clinical efficacy of acalabrutinib and acalabrutinib-based combinations for the treatment of patients with relapsed/refractory and treatment-naïve CLL. We delineate the safety profile of the drug, describe side effects of interest and discuss the clinical management of patients receiving acalabrutinib. Due to its efficacy and the favorable safety profile, acalabrutinib has emerged as a viable therapy option in the current landscape of multiple approved treatments for CLL.
KW - Acalabrutinib
KW - Bruton tyrosine kinase inhibitor
KW - Chronic lymphocytic leukemia
UR - http://www.scopus.com/inward/record.url?scp=85126307869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126307869&partnerID=8YFLogxK
U2 - 10.2147/OTT.S303060
DO - 10.2147/OTT.S303060
M3 - Review article
C2 - 35002256
AN - SCOPUS:85126307869
SN - 1178-6930
VL - 14
SP - 5507
EP - 5519
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -